Legend Biotech· @LegendBiotech · X·· 2026-06-14AI 评分40
AI 导读
#LegendNews：在@EHA_Hematology上，我们展示了LB2501的一期数据，这是我们研究中的体内CD19/CD20双靶点CAR-T疗法。结果显示，单次输注后具有临床活性，且迄今为止安全性良好。阅读更多：https://bit.ly/4erUIIR
正文
#LegendNews: At @EHA_Hematology, we presented Phase 1 data for LB2501, our investigational in vivo CD19/CD20 dual-targeting CAR-T therapy. Results showed clinical activity after a single infusion and a favorable safety profile to date. Read more: https://bit.ly/4erUIIR
来源：Legend Biotech · x.com